Abstract 907: The efficiency of Nek2 siRNA for liver metastasis of pancreatic cancer

Abstract Background: Nek2 (NIMA-related kinase 2) is a member of the serine/threonine kinase family, which related to the essential mitotic regulator NIMA. Nek2 is involved in cell division and mitotic regulation by centrosome splitting. We reported that the efficiency of Nek2 as molecular target for several cancers, such as cholangiocarcinoma, breast cancer and colorectal cancer. Methods: We examined the effect of Nek2 siRNA treatment on the tumor of pancreatic cancer in xenograft mouse model. We also challenged Nek2 siRNA in the liver metastasis model of pancreatic cancer. Results and Discussion: Nek2 siRNA suppressed the growth of tumors in xenograft pancreas cancer model. In liver metastasis model, Nek2 siRNA decreased the number of metastasis and resulted in reduction of metastasis volume. Liver metastasis is one of the major undesirable complications frequently associated with inoperable cases. The Nek2 suppression with siRNA is also effective in the inhibition of liver metastasis of pancreas cancer. Conclusions: Nek2 plays a critical role in tumorigenic growth of various cancers, and inhibition of Nek2 expression with its siRNA causes suppression of cancer growth. Our data provides a strong rationale for the further investigation of Nek2 inhibitors as a new cancer therapy, holding the potential to provide regression of multiple human malignancies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 907. doi:1538-7445.AM2012-907